HIV Vaccines

Development of Potential Preventive Vaccine Pursued

Published in AIDS Weekly, April 10th, 2000

The Immune Response Corp. (IMNR), Carlsbad, California, announced data from preclinical animal studies of a potential new vaccine consisting of the company's HIV immunogen, Remune (whole-killed HIV depleted of gp120 coat proteins in Incomplete Freund's Adjuvant) combined with a immunostimulatory sequence of DNA.

These data were presented at the "International Workshop on Immunotherapy in HIV Infection" held in Israel during March 2000. This potential new preventive HIV vaccine appears to boost key elements of the immune response in animals, including both T-helper and T-killer cell activity that may be involved in protection against HIV infection.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2000-04-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry